Who
Ilan Hadar
Chairman and CEO
Company insider
Files Form 4 as: Chairman and CEO, Silexion Therapeutics; CFO & Country Manager, Foamix Pharmaceuticals; CFO and Country Manager, Yarrow Bioscience.
In numbers
- Trades disclosed
- 40
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $153K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 1 Jan 2018
- Last trade
- 4 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 8 Jun 2026 | SLXN Silexion TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | SLXN Silexion TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | SLXN Silexion TherapeuticsBiotechnology | SEC FORM 4 Code A | —64,350 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | SLXN Silexion TherapeuticsBiotechnology | SEC FORM 4 Code A | —64,350 at $0.00 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —5,469 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —24,125 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —18,000 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —202,004 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —60,389 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —196,205 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —35,093 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —94,996 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —96,365 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticals | SEC FORM 4 Code D | —14,077 | filing |
| 9 Mar 2020filed 11 Mar 2020 | Foamix Pharmaceuticals | SEC FORM 4 Code D | —116,501 | filing |
| 9 Mar 2020filed 11 Mar 2020 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,239 | filing |
| 9 Mar 2020filed 11 Mar 2020 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,291 | filing |
| 9 Mar 2020filed 11 Mar 2020 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,663 | filing |
| 9 Mar 2020filed 11 Mar 2020 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —119,667 | filing |
News
No headline names them, or the companies they trade most, lately.